Table 2.

Predicted and observed proportions of SARS-CoV-2 anti-Spike seroconversion according to hematologic diagnosis, therapy, and immunoglobulin G (IgG) levels.

No. of patients	ADiagnosis of indolent lymphoma/CLL	BB-cell-depleting therapy	CIgG <700 mg/dl	Predicted probability	Observedproportion
24	Yes	Yes	Yes	0.11	0.17
20	Yes	Yes	No	0.22	0.15
7	Yes	No	Yes	0.29	0.29
10	Yes	No	No	0.48	0.50
31	No	Yes	Yes	0.52	0.58
22	No	Yes	No	0.71	0.64
44	No	No	Yes	0.77	0.70
121	No	No	No	0.89	0.91

CLL, chronic lymphocytic leukemia.